<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We treated 21 elderly patients with high-risk <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> (n = 14) or secondary <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (n = 7) with 2 mg of melphalan orally once a day until a complete peripheral response was obtained or until there was evidence of treatment failure </plain></SENT>
<SENT sid="1" pm="."><plain>We observed seven (30%) complete and two (10%) partial peripheral responses occurring within 4-16 weeks and lasting for 12 + to 55 weeks </plain></SENT>
<SENT sid="2" pm="."><plain>In relapse, retreatment was successful in most of the patients </plain></SENT>
<SENT sid="3" pm="."><plain>Responses were associated with the absence of complex cytogenetic abnormalities and with a <z:mpath ids='MPATH_458'>normal</z:mpath> or reduced bone marrow cellularity </plain></SENT>
</text></document>